Cancer Family
B-Cell Malignant Neoplasm
CI-CAN-00000070Explore in graph →
Hematologic2,083 active trials46 approved drugs301 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000070Explore in graph →
Clinical trials
7,466 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,167)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00422656 | Perifosine in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia | completed | Phase 2 | 37 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 26, 2017 | clinicaltrials |
| NCT01083602 | Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma(MACS1271) | completed | Phase 2 | 55 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 21, 2017 | clinicaltrials |
| NCT00461045 | Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma | completed | Phase 2 | 15 | CelgeneINDUSTRY | 1 | Dec 19, 2017 | clinicaltrials |
| NCT00438854 | Dasatinib in Relapsed Chronic Lymphocytic Leukemia | completed | Phase 2 | 15 | Massachusetts General HospitalOTHER | 1 | Dec 13, 2017 | clinicaltrials |
| NCT00349778 | High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma | completed | Phase 2 | 102 | Stanford UniversityOTHER | 1 | Dec 12, 2017 | clinicaltrials |
| NCT01057225 | Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma | completed | Phase 1 / Phase 2 | 64 | Mayo ClinicOTHER | 1 | Dec 12, 2017 | clinicaltrials |
| NCT02252146 | Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88 L265P Mutation | completed | Phase 1 / Phase 2 | 6 | Idera Pharmaceuticals, Inc.INDUSTRY | 1 | Dec 12, 2017 | clinicaltrials |
| NCT00764517 | Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma | completed | Phase 2 | 57 | OHSU Knight Cancer InstituteOTHER | 1 | Dec 11, 2017 | clinicaltrials |
| NCT00060424 | Fludarabine Phosphate and Total-Body Irradiation Before Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia | completed | Phase 2 | 21 | Fred Hutchinson Cancer CenterOTHER | 2 | Dec 8, 2017 | clinicaltrials |
| NCT00565981 | A Pilot Trial With Subcutaneous Alemtuzumab and Oral Fludarabinephosphate for the Determination of Safety, Efficacy and Molecular Profiling for the Prediction of Response | completed | Phase 2 | 10 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | Dec 7, 2017 | clinicaltrials |
| NCT00556452 | Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen | completed | Phase 1 / Phase 2 | 46 | University of Michigan Rogel Cancer CenterOTHER | 1 | Dec 5, 2017 | clinicaltrials |
| NCT00867087 | Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma | completed | Phase 2 | 64 | PfizerINDUSTRY | 6 | Dec 5, 2017 | clinicaltrials |
| NCT00530218 | Ganciclovir by Infusion and by Mouth in Treating Patients With Cytomegalovirus After Donor Bone Marrow Transplant | completed | Phase 2 | 61 | City of Hope Medical CenterOTHER | 1 | Dec 2, 2017 | clinicaltrials |
| NCT00156013 | Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL) | completed | Phase 1 / Phase 2 | 33 | Oncology Specialists, S.C.OTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT00186628 | Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD | completed | Phase 2 | 36 | Stanford UniversityOTHER | 1 | Nov 28, 2017 | clinicaltrials |
| NCT01626352 | Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy | completed | Phase 2 | 22 | SCRI Development Innovations, LLCOTHER | 1 | Nov 22, 2017 | clinicaltrials |
| NCT00577512 | 2006-32 Phase II Study of Rapidly Recycled High Dose DTPACE | completed | Phase 2 | 4 | University of ArkansasOTHER | 1 | Nov 20, 2017 | clinicaltrials |
| NCT01524978 | A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers | completed | Phase 2 | 208 | Hoffmann-La RocheINDUSTRY | 6 | Nov 20, 2017 | clinicaltrials |
| NCT01460940 | A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma | completed | Phase 2 | 24 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Nov 14, 2017 | clinicaltrials |
| NCT02419118 | "Monoclonal Antibodies for Treatment of Multiple Myeloma. Emphasis on the CD38 Antibody Daratumumab "(DARA) | completed | Phase 2 / Phase 3 | 4 | Vejle HospitalOTHER | 1 | Nov 7, 2017 | clinicaltrials |
| NCT01611259 | Rituximab Plus Lenalidomide in Patients With Mucosa Associated Lymphoid Tissue | completed | Phase 2 | 50 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | Nov 6, 2017 | clinicaltrials |
| NCT01562977 | Study to Evaluate Efficacy and Tolerance of R-GemOx in DLBCL and MCL(RGemOx) | completed | Phase 2 | 82 | Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaOTHER | 1 | Oct 30, 2017 | clinicaltrials |
| NCT02046915 | Phase II Multicenter, Open-label, Single Arm Clinical Study of Pomalidomide and dexamethasonE and Cyclophosphamide(PERSPECTIVE) | completed | Phase 2 | 60 | University Hospital TuebingenOTHER | 1 | Oct 30, 2017 | clinicaltrials |
| NCT02132624 | CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial. | completed | Phase 1 / Phase 2 | 15 | Uppsala UniversityOTHER | 1 | Oct 30, 2017 | clinicaltrials |
| NCT00006184 | Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Oct 20, 2017 | clinicaltrials |
| NCT00401817 | Bevacizumab + CHOP-Rituximab in Untreated Mantle Cell Lymphoma | completed | Phase 2 | 11 | Weill Medical College of Cornell UniversityOTHER | 1 | Oct 20, 2017 | clinicaltrials |
| NCT00899847 | Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG | completed | Phase 2 | 9 | Stanford UniversityOTHER | 1 | Oct 20, 2017 | clinicaltrials |
| NCT02301364 | Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL) | completed | Phase 2 | 4 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 19, 2017 | clinicaltrials |
| NCT01239394 | Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma | completed | Phase 2 | 43 | Massachusetts General HospitalOTHER | 1 | Oct 18, 2017 | clinicaltrials |
| NCT00081939 | UARK 2003-33, Total Therapy III | completed | Phase 2 | 303 | University of ArkansasOTHER | 1 | Oct 17, 2017 | clinicaltrials |
| NCT00054353 | Reduced-Intensity Conditioning Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma | completed | Phase 1 / Phase 2 | 16 | Fred Hutchinson Cancer CenterOTHER | 2 | Oct 16, 2017 | clinicaltrials |
| NCT00476047 | Tositumomab and Iodine I 131 Tositumomab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First Remission | completed | Phase 2 | 16 | Fred Hutchinson Cancer CenterOTHER | 1 | Oct 12, 2017 | clinicaltrials |
| NCT01682044 | Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma | completed | Phase 2 | 20 | Roswell Park Cancer InstituteOTHER | 1 | Oct 9, 2017 | clinicaltrials |
| NCT01481129 | Akt Inhibitor MK2206 in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | completed | Phase 2 | 22 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2017 | clinicaltrials |
| NCT01593410 | Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma | completed | Phase 2 | 194 | CelgeneINDUSTRY | 1 | Sep 20, 2017 | clinicaltrials |
| NCT01369849 | Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 1 / Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Sep 15, 2017 | clinicaltrials |
| NCT01116193 | Repeat-dose Study of Lenalidomide (Revlimid ®) Plus Dexamethasone in Patients With Lymphoblastic Leukemia(RV-405 LAL) | completed | Phase 2 | 10 | Institut de Cancérologie de la LoireOTHER | 1 | Sep 14, 2017 | clinicaltrials |
| NCT01078142 | Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma(BERT) | completed | Phase 1 / Phase 2 | 39 | Georg Hess, MDOTHER | 1 | Sep 11, 2017 | clinicaltrials |
| NCT00410605 | Bevacizumab, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Stage II or III Multiple Myeloma | completed | Phase 2 | 39 | National Cancer Institute (NCI)NIH | 1 | Sep 1, 2017 | clinicaltrials |
| NCT00511238 | Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma | completed | Phase 2 | 312 | AmgenINDUSTRY | 2 | Aug 31, 2017 | clinicaltrials |
| NCT00670631 | Tandem Transplantation in Multiple Myeloma (MM) Patients With <12 Months of Prior Treatment | completed | Phase 2 | 46 | Guido TricotOTHER | 0 | Aug 31, 2017 | clinicaltrials |
| NCT01866293 | Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma | completed | Phase 1 / Phase 2 | 11 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 30, 2017 | clinicaltrials |
| NCT00073918 | Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | completed | Phase 2 | 111 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 18, 2017 | clinicaltrials |
| NCT02013817 | CHAIROS Study A Study of MabThera/Rituxan (Rituximab) Maintenance Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Naive to Chemotherapy | completed | Phase 2 | 43 | Hoffmann-La RocheINDUSTRY | 1 | Aug 18, 2017 | clinicaltrials |
| NCT00472420 | A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Mantle Cell Lymphoma. | completed | Phase 2 | 48 | Hoffmann-La RocheINDUSTRY | 1 | Aug 15, 2017 | clinicaltrials |
| NCT00531284 | Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma | completed | Phase 1 / Phase 2 | 184 | AmgenINDUSTRY | 1 | Aug 15, 2017 | clinicaltrials |
| NCT00738374 | A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia. | completed | Phase 2 | 97 | Hoffmann-La RocheINDUSTRY | 1 | Aug 15, 2017 | clinicaltrials |
| NCT00702403 | Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML | completed | Phase 1 / Phase 2 | 40 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 10, 2017 | clinicaltrials |
| NCT01339572 | Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation | completed | Phase 2 | 72 | University of FloridaOTHER | 1 | Aug 1, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Dec 26, 2017source: clinicaltrials